APP
MDGL icon

Avantax Planning Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Avantax Planning Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2
Closed – – 830
2018
Q3 		$0 Buy
+2
New +$502 ﹤0.01% 1459
2018
Q2 		– Sell
-2
Closed – – 958
2018
Q1 		$0 Buy
+2
New +$247 ﹤0.01% 1846

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avantax Planning Partners's MDGL Position: Q4 2018 in Review

Avantax Planning Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2018, closing a stake of 2 shares.

Avantax Planning Partners first reported a position in MDGL in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2018. 136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

  • Avantax Planning Partners reported no remaining Madrigal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 2 Madrigal Pharmaceuticals shares in Q4 2018.
  • Avantax Planning Partners first reported a position in Madrigal Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Madrigal Pharmaceuticals position peaked at $0 in Q3 2018.
  • 136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.